RMTC Grants Full Accreditation To University Of Kentucky Equine Analytical Chemistry Laboratory

The Racing Medication & Testing Consortium (RMTC) announced Tuesday that it has granted full laboratory accreditation to the University of Kentucky Equine Analytical Chemistry Laboratory (UK-EACL). The RMTC's Board of Directors voted unanimously in favor of accreditation at its summer meeting, which was conducted virtually on Sept. 13. The UK-EACL is directed by Dr. Scott Stanley.

RMTC laboratory accreditation is earned through a rigorous review process by independent experts of the laboratory's protocols, staffing, and facilities. Candidate laboratories must also perform successfully in analyzing external quality assurance samples.

The UK-EACL joins the eight other RMTC-accredited laboratories, whose testing covers more than 92 percent of all pari-mutuel races in the United States.

“The RMTC commends Dr. Stanley, his staff, and the University of Kentucky for undertaking the accreditation process and for their ongoing commitment to promoting the safety and integrity of horse racing,” said RMTC Chairman Alex Waldrop.

“We are proud of this milestone, which attests to the high standards set by Dr. Stanley, and it is gratifying to know this lab is positioned to serve the broader industry in the best way possible,” said Dr. Nancy Cox, dean of the University of Kentucky College of Agriculture, Food and Environment.

The RMTC is a 501(c) 3 organization comprised of 23 industry stakeholder organizations with a shared commitment to engage in research, education, and advocacy for science-based initiatives that promote the health and safety of the racehorse and the integrity of competition. More information can be found at RMTCnet.com.

The post RMTC Grants Full Accreditation To University Of Kentucky Equine Analytical Chemistry Laboratory appeared first on Horse Racing News | Paulick Report.

Source of original post

Here’s The Difference Between Pioneer, Generic, And Compounded Medications For Horses – And Why It Matters

Compounded medications for horses have been in the headlines in this and other publications a lot in recent years, especially in the wake of the 2020 federal indictments focusing on the use of misbranded drugs in racehorses. For a lot of horsemen though, it's not always clear from looking at a drug bottle or box what type of drug they're dealing with, and whether they should have concerns about its safety and legality.

Dr. Dionne Benson, chief veterinary officer for The Stronach Group and former executive director of the Racing Medication and Testing Consortium, presented a continuing education seminar for trainers in July to help them distinguish the different categories a drug may fall into and to determine if the product they're looking at is illegal.

When dealing with prescription (sometimes called “legend”) drugs, the first approved version of a new drug is called a pioneer drug. This is a substance that has been legally recognized by the Food and Drug Administration as a new animal drug and has been subjected to considerable testing to demonstrate its safety and efficacy, as well as the purity of its manufacturing process and the stability or shelf life of the drug. They also must show that the manufacturing process is consistent, and the concentration and purity of the drug doesn't change from batch to batch. Pioneer drugs also must show considerable research to validate their suggested doses and uses, and must meet rigorous requirements regarding their package labeling and advertising to be sure consumers are being presented with accurate and complete information.

The FDA approval process for new drugs is long, arduous, and expensive, so to give drug makers an incentive to go through it, they are permitted temporary patents on new substances. This means that for a limited number of years, the company that went through the approval process will be the only one that can legally produce the drug, allowing them to better recoup some of their expenditures in the approval process.

A generic medication is subject to all the same requirements regarding safety and efficacy, and may only be legally produced when the patent on the pioneer version of the drug has expired.

Both types of medications are also subject to adverse event reporting, so there is a public record of any negative side effects or bad reactions to a given drug or batch of drugs and those events can be investigated.

Compounded drugs aren't subject to any of that federal oversight.

Compounding may only be legally done in certain narrow parameters. A compounding pharmacy may only make a drug in response to a prescription a veterinarian has written to treat a specific condition in a specific animal, and it should only take place when there is no legend drug (either a pioneer or a generic) available to serve the patient's needs. Compounders can legally add flavoring to drugs to make them easier to administer, or take a drug traditionally offered in one form like a paste and make it into another, like a powder. In some limited circumstances, a compounder may legally mix two medications to reduce the amount of needle sticks a horse has to endure. In none of those situations should a compounder have large amounts of pre-formulated compounds sitting on the shelf awaiting an order – that, in the eyes of the FDA, is manufacturing. If an FDA-approved drug is no longer being manufactured or is on back order though, a compounder may make small batches of it but should not be in the business of mass manufacture.

“Compounded medications are legal under some circumstances,” said Benson. “Your vets use them every day and in the large majority of those cases they're using them appropriately.”

Benson has seen a number of examples of illegal compounds floating around the track however – sometimes sold online and sometimes peddled by sales reps.

One of the biggest areas of confusion seems to be what constitutes a generic drug. Compounded omeprazole products are a favorite of compounding pharmacies to produce in bulk, in part because horsemen are always looking for cheaper alternatives to the pioneer drug. But Benson said the patent on Gastrogard and Ulcergard, the pioneer form of the drug, hasn't run out yet, so all those “knock off” versions which people may think of as “generics” are actually illegal.

[Story Continues Below]

Compounders are also fond of getting around this restriction by combining omeprazole with another ulcer drug like ranitidine, with the result often being priced more cheaply than pioneer omeprazole.

“The funny thing about that one is if you're combining omeprazole and ranitidine you're actually deactivating one of them,” said Benson.

Omeprazole works by reducing acid secretion, while ranitidine works by neutralizing acid. You don't need both, and they tend to be used in different types of ulcer cases.

Of course, Benson said, it's true that the FDA isn't likely to show up at your barn and ask to examine your prescription bottles (although, the federal case demonstrates they will take an interest in racing now and then). So why should horsemen worry about the technicalities of drug production?

Benson said that the illegal compounds she has seen often come along with safety concerns. Compounders mass producing a legend drug and selling it as a “generic” version aren't having their products tested like approved generic drug manufacturers, and testing by the RMTC suggests the amount of active ingredient in these illegal substances can be wildly mismatched to what's on the label. Benson recalled one bottle of clenbuterol that had ten times the labeled concentration of the drug, which was “getting into toxic ranges.” Another test of a triamcinolone bottle found it contained just .01 percent of its labeled concentration.

Another trouble with unauthorized mass manufacturers of prescription drugs is that there's no assurance of consistency from batch to batch of the medication, so just because a horseman has given a drug from a pharmacy once with no issue doesn't mean the next batch will be the same.

Many of these illegal substances can also be missing key safety information on their packaging. Benson cited Gastrotec, an omeprazole/misoprostol product which she said is still in circulation, despite FDA warnings about it.

“What's terrifying about this medication is the misoprostol,” she said, pointing out that drug is half of the abortion cocktail used in humans. “In veterinary school, you can't touch this stuff without gloves. All the women on the backside, they're given this to give to the horse, and what's the first thing we do? We put the tube in our mouth to pull off the cap and give it to the horse.”

There was no warning about these human health risks on the boxes or tubes of Gastrotec, Benson said.

Benson said she believes trainers have a responsibility to educate themselves about what is and isn't permissible in the drug-making world. Just acquiring a product from a sales representative or a veterinarian isn't a guarantee it is legal.

“Oftentimes we assume whatever the doctor or veterinarian says is right,” she said. “We don't want to make them mad; we just go along with it. But realistically it's your license on the line. Very rarely does a vet get called into a hearing or have to call an owner when a horse dies.”

The post Here’s The Difference Between Pioneer, Generic, And Compounded Medications For Horses – And Why It Matters appeared first on Horse Racing News | Paulick Report.

Source of original post

Same Rules, New Lab: Maryland’s Leading Trainer Gonzalez Notified Of Two Dexamethasone Positives

Claudio Gonzalez, Maryland's leading trainer for the last four years, scratched all six of his runners entered to race on Sunday, July 4, at Pimlico racetrack in Baltimore, Md., after being notified of two positive tests for the corticosteroid dexamethasone.

Gonzalez said he learned of the positive tests on Saturday, July 3. That night, the Maryland Thoroughbred Horsemen's Association issued the following advisory to trainers:

“Horsemen are advised of the following regarding the use of dexamethasone, a commonly used corticosteroid with anti-inflammatory properties.

“Dexamethasone has a 72-HOUR withdrawal guideline for intramuscular and intravenous administration of dexamethasone sodium phosphate or oral administration of dexamethasone. The dosing specification is 0.05 milligrams per kilogram regardless of the route of administration.

“Under the Association of Racing Commissioners International Uniform Classification Guidelines and Recommended Penalties Model Rules, dexamethasone is a Class 4 substance in the Class C penalty category. In Maryland, a first offense carries a minimum fine of $1,000 absent mitigating circumstances for a trainer and disqualification of the horse and loss of purse.”

Gonzalez admitted that the veterinarians he employs were giving the anti-inflammatory at 48 hours, but with a lower dose.

“The recommendation is 72 hours and 22 milligrams,” said Gonzalez. (Note:  the .05 milligram per kilogram dosing specification converts to about 22 milligrams for a 1,000-pound horse.) “We go 48 hours and give only 10 (milligrams). We give half at two days. Since 2014, they (the vets) have done the same. They've treated 3,000 horses a year from 2014 and never had one positive in Maryland until now.”

These would be the first medication charges against Gonzalez since he received a warning in 2016 for an overage of the ulcer treatment, omeprazole – the only medication violation on his record at www.thoroughbredrulings.com.

Dexamethasone guidelines in Maryland have not changed recently, according to J. Michael Hopkins, executive director of the Maryland Racing Commission.

What has changed is Maryland's official testing lab. Hopkins said when the contract with Truesdail Laboratories of Irvine, Calif., expired in April 2021, the commission switched to Industrial Laboratories in Wheat Ridge, Colo. No formal announcement or advisory on the change of labs was issued by the commission or Maryland Thoroughbred Horsemen's Association.

“They changed the lab,” said Gonzalez. “It can be a big difference.”

Several states have now dropped Truesdail as their official testing laboratory since a 2015 quality control audit by the Indiana Horse Racing Commission found that seven positive tests were missed over a 26-day period, including two for betamethasone. Indiana switched to Industrial, as did the West Virginia Racing Commission. The Arkansas Racing Commission had its testing shifted to Industrial after Truesdail's accreditation was suspended in April 2020 by the Racing Medication and Testing Consortium. Truesdail  has not sought to re-gain its RMTC accreditation.

Shortly after the switch from Truesdail to Industrial, Hopkins said, an unspecified number of positives for Amicar, an adjunct bleeder medication, were called. The Maryland Thoroughbred Horsemen's Association then issued the following advisory:

“Effective immediately, horsemen are urged to discontinue the use of any and all adjunct bleeder medications for horses in training, including in particular, aminocaproic acid—commonly called Amicar.

“Amicar and several other adjunct bleeder medications were placed on the Prohibited List in 2013 under the Association of Racing Commissioners International Uniform Classification Guidelines for Foreign Substances and Recommended Penalties Model Code and the National Uniform Medication Program. Aminocaproic acid, for example is a Class 4 substance and penalty Class C.

“It is important to understand that these medications cannot be regulated by withdrawal time guidance and/or a testing threshold and their use, no matter how far in advance of a race, may trigger a positive post-race test.

“Any trainer who chooses to continue the use of these medications for training in the future will run the risk of a post-race positive test.”

Hopkins said he couldn't comment on any specifics involving the Amicar or dexamethasone positives because of ongoing investigations.

Gonzalez is leading the current Laurel and Pimlico meeting with 27 wins from 110 starts, more than doubling the number of wins by his closest pursuers. Gonzalez said he plans to ask for a split sample to confirm the findings by Industrial and fight the charges if a formal complaint is filed against him.

The post Same Rules, New Lab: Maryland’s Leading Trainer Gonzalez Notified Of Two Dexamethasone Positives appeared first on Horse Racing News | Paulick Report.

Source of original post

Broberg: Possible ‘Career Ender’ Turned Out To Be False Positives From LSU Laboratory

Leading North American trainer Karl Broberg is calling for a change in the testing laboratory in Louisiana after learning that split samples from a horse in his barn that originally tested positive for three drugs – including a Class 1 that he said would have been a “career ender” for him – all came back negative.

Broberg, ranked first or second in North American wins each year since 2013, was notified by stewards at Delta Downs in late December that Tiz One Fee, a 7-year-old Louisiana-bred mare who was one of four winners he saddled on opening night at the Vinton, La., track on Nov. 24, tested positive for the Class 1 drug oxycodone, Class 2 drug levamisole and Class 2 drug citalopram. The classifications are defined by the Association of Racing Commissioners International, with Class 1 being the most severe drug category in racing.

The Equine Medication Surveillance Laboratory at the Louisiana State University School of Veterinary Medicine reported 0.143 ng/ml of oxycodone in plasma, 0.515 ng/ml of citalopram in plasma and 0.148 ng/ml of levamisole in plasma. Oxycodone is an opioid pain reliever, citalopram is used as an anti-depressant and levamisole is used as a dewormer in livestock and as an immunostimulant.

Notified on Dec. 28, Broberg sent a check for $3,750 on Jan.  12 to the testing laboratory at the Kenneth L. Maddy Equine Analytical Chemistry Laboratory at the University of California at Davis to have the split samples tested for confirmatory purposes.

On Monday, Broberg said, the Louisiana State Racing Commission notified him all three tests from the Maddy Lab came back negative.

“They were false positives,” Broberg said. “That horse was in my barn for a couple of months and I knew there was no way.”

Broberg said stewards did not conduct a barn search before or after stewards told him Tiz One Fee had tested positive for three different drugs at the state's official lab at LSU.

“That's the most ludicrous part of the whole thing,” he said. “If someone is with a Class 1, 2 or 3, they're searching that barn prior to the trainer being notified. That never happened.”

In addition to being out the $3,750 for the split sample, Broberg said the false positives cost him an opportunity to run Tiz One Fee in the $50,000 Premier Lady Starter Stakes at Delta Downs on Feb. 10. “She would have been 2-5 in that spot,” Broberg said. “I haven't been able to run that horse since they said she tested positive. I begged and pleaded and offered to send off hair samples (for testing) on this horse and said, 'You can not be this punitive.'”

Tiz One Fee did run once after the Nov. 24 race but before the original test came back positive.

“There's no way they can keep whatever contract they have with that laboratory,” Broberg said. “I know another trainer has a positive for one of the drugs, because he called me saying 'What is this? I heard you're dealing with some craziness.'”

The LSU laboratory is ISO 17025 accredited for technical competence but has never applied for accreditation with the Racing Medication and Testing Consortium. The lab at UC Davis is fully accredited with the RMTC.

Broberg, leading trainer by North American wins from 2014-'19 and with 3,883 career wins from 15,911 starts since 2009, said he has never been suspended for any medication violation. His record at www.thoroughbredrulings.com does show a number of medication violations that resulted in fines, the most recent for the Class 4 drug dextromethorphan in July 2019 in Louisiana. Broberg maintains stables in multiple states and said this case had potentially devastating consequences.

“Two months with no sleep,” he said. “This could have been a career ender. Shit like this needs to be brought to light.”

Broberg said he is considering taking legal action. “A hundred percent. I'd be foolish not to,” he said.

Officials at the Louisiana State Racing Commission could not be reached for comment.

The post Broberg: Possible ‘Career Ender’ Turned Out To Be False Positives From LSU Laboratory appeared first on Horse Racing News | Paulick Report.

Source of original post

Verified by MonsterInsights